Lilley submitted the drug plasma inflammation to treat migraines

Lilly has filed an application in the United States to sell plasmaitis for acute treatment of migraines in adults, with or without signs.
plasmaitis is described as a first-class, research-based, oral, centrally permeable, selective serotonin 5 - HT1F astrist, structurally and institutionally different from other recognized migraine therapies, and lacks vascular constrictive activity associated with some other therapies.
approved, the drug would represent the first major innovation in acute migraine treatment in more than two decades. "The application includes data from two third-stage single-targeted studies. Data
the third phase of the SPARTAN trial showed that patients treated with plasmaitis had a higher proportion of migraines than those treated with plasmaitis two hours after the first dose compared to placebos.
results observed in all three dose trials were statistically significant: 28.6 per cent for 50 mg, 31.4 per cent for 100 mg, 38.8 per cent for 200 mg and 21.3 per cent for placebo.
also announced that it was preparing to apply by the end of the year to expand the use of emgoy, including preventive treatment for intermittent headaches in adults.
, which was approved in September to prevent migraines in adults and was awarded a breakthrough treatment for occasional headaches, could speed up its review. Currently, the United States does not have approved preventive treatment for intermittent headaches, highlighting significant unsealed demand in this area. (This net special draft)